Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort ; volume:26 ; number:1 ; day:28 ; month:9 ; year:2024 ; pages:1-16 ; date:12.2024
Arthritis Research & Therapy ; 26, Heft 1 (28.9.2024), 1-16, 12.2024
- Creator
-
Ramonda, Roberta
Lorenzin, Mariagrazia
Chimenti, Maria Sole
Atzeni, Fabiola
Semeraro, Angelo
D’Angelo, Salvatore
Selmi, Carlo
Ortolan, Augusta
Marchesoni, Antonio
Manara, Maria
Luchetti Gentiloni, Michele Maria
Santo, Leonardo
Salvarani, Carlo
Cauli, Alberto
Rossini, Maurizio
Amato, Giorgio
Cozzi, Giacomo
Scagnellato, Laura
Ferraioli, Mario
Carriero, Antonio
Fracassi, Elena
Giorgio, Francesco
Doria, Andrea
Foti, Rosario
Carletto, Antonio
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-024-03401-x
- URN
-
urn:nbn:de:101:1-2412142101086.581428944293
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ramonda, Roberta
- Lorenzin, Mariagrazia
- Chimenti, Maria Sole
- Atzeni, Fabiola
- Semeraro, Angelo
- D’Angelo, Salvatore
- Selmi, Carlo
- Ortolan, Augusta
- Marchesoni, Antonio
- Manara, Maria
- Luchetti Gentiloni, Michele Maria
- Santo, Leonardo
- Salvarani, Carlo
- Cauli, Alberto
- Rossini, Maurizio
- Amato, Giorgio
- Cozzi, Giacomo
- Scagnellato, Laura
- Ferraioli, Mario
- Carriero, Antonio
- Fracassi, Elena
- Giorgio, Francesco
- Doria, Andrea
- Foti, Rosario
- Carletto, Antonio
- SpringerLink (Online service)
Other Objects (12)
Secukinumab: A Review in Psoriatic Arthritis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
Vitiligo with Progressive Repigmentation during Secukinumab Treatment in a Patient with Psoriatic Arthritis: A Case Report
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)
Secukinumab: A Review in Psoriatic Arthritis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
Vitiligo with Progressive Repigmentation during Secukinumab Treatment in a Patient with Psoriatic Arthritis: A Case Report
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)
Secukinumab: A Review in Psoriatic Arthritis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry
Vitiligo with Progressive Repigmentation during Secukinumab Treatment in a Patient with Psoriatic Arthritis: A Case Report
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies